BioCardia Reports Third Quarter 2026 Business Highlights and Financial Results
BioCardia, Inc. (BCDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BioCardia Reports Third Quarter 2026 Business Highlights and Financial Results Sunnyvale, Calif. – November 12, 2026 - BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases
How this was made
The 30-second read
Why it matters
The disclosed cash runway into 2027 and upcoming regulatory submissions set short‑term risk while offering a catalyst pipeline.
Market read
Primary 8‑K filing provides fresh financial and regulatory data, essential for traders evaluating short‑term risk and long‑term upside.
What to watch
The partnership with CART‑Tech and the potential for the Helix platform to serve other biologics may broaden revenue beyond CardiAMP.
BioCardia Q3 2026: net loss of $(1,817) thousand, cash of $2,224 thousand, company cites runway into 2027
The company reports no revenue. The quarterly net loss widened versus Q3 2025 while the nine-month net loss narrowed. Cash and equivalents of $2,224 thousand are against nine-month cash used in operations of $5.1 million, and the company states runway into 2027. Regulatory milestones are the main near-term items.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Research and development expenses, three months ended Sept 30, 2026GAAP | $1.24M | – | – |
| Selling, general and administrative expenses, three months ended Sept 30, 2026GAAP | $600K | – | – |
| Total costs and expenses, three months ended Sept 30, 2026GAAP | $1.83M | – | – |
| Operating loss, three months ended Sept 30, 2026GAAP | −$1.83M | – | – |
| Total other income, net, three months ended Sept 30, 2026GAAP | $18K | – | – |
| Net loss, three months ended Sept 30, 2026GAAP | −$1.82M | – | – |
| Net loss per share, basic and diluted, three months ended Sept 30, 2026GAAP | $(0.12) per share | – | – |
| Net cash used in operations, three months ended Sept 30, 2026other | $1.7M | – | – |
| Research and development expenses, nine months ended Sept 30, 2026GAAP | $3.36M | – | – |
| Selling, general and administrative expenses, nine months ended Sept 30, 2026GAAP | $2.36M | – | – |
| Total costs and expenses, nine months ended Sept 30, 2026GAAP | $5.72M | – | – |
| Operating loss, nine months ended Sept 30, 2026GAAP | −$5.72M | – | – |
| Total other income, net, nine months ended Sept 30, 2026GAAP | $35K | – | – |
| Net loss, nine months ended Sept 30, 2026GAAP | −$5.69M | – | – |
| Net loss per share, basic and diluted, nine months ended Sept 30, 2026GAAP | $(0.45) per share | – | – |
| Net cash used in operations, nine months ended Sept 30, 2026other | $5.1M | – | – |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
What drove it
- Company explanation: R&D for the three months rose to $1.2 million from $936,000, primarily due to a bonus accrual at a higher level, coupled with increased expenses from regulatory activities to advance CardiAMP in Japan and enrollment in the CardiAMP HF II Trial.
- Company explanation: R&D for the nine months decreased to $3.4 million from $3.8 million, primarily due to closeout of the CardiAMP Heart Failure Trial, partially offset by early enrollment in the CardiAMP Heart Failure II Trial and regulatory activities to advance CardiAMP in Japan.
- SG&A rose to $600,000 for the three months from $552,000. The company describes SG&A for the nine months as consistent at $2.4 million in both periods.
- Company explanation: the nine-month net loss decrease to $5.7 million from $6.2 million was primarily due to lower research and development expenses.
- Regulatory: the company states it completed the process with Japan's PMDA concerning the application materials required for regulatory approval in Japan, and that questions remaining in advance of submission have been addressed to PMDA's satisfaction.
- Regulatory: FDA accepted the revised Pre-Submission for Helix in October. The company expects to hear from the FDA in the next six weeks and expects to complete the De Novo submission in the first quarter of 2027.
Concerns
- The company reports no revenue in the document. Cash and cash equivalents of $2,224 thousand compare with nine-month net cash used in operations of $5.1 million.
- Three-month net loss rose to $(1,817) thousand from $(1,483) thousand, while the nine-month net loss narrowed to $(5,689) thousand from $(6,244) thousand.
- Net loss per share for the three months was $(0.12), compared with $(0.24) in the prior-year quarter. Weighted-average shares were 15,137,085 for the three months ended Sept 30, 2026, against 6,277,848 a year earlier (share counts are shown here as printed, for context only).
- Total stockholders' equity was $835 thousand at Sept 30, 2026, compared with $895 thousand at Dec 31, 2025.
- The company's own runway statement is 'into 2027'. The document contains no further financing detail.
- The company's forward-looking statements cite the ability to raise additional funding and slower-than-targeted enrollment as risks.
What to watch
- Submission of CardiAMP cell therapy to Japan's PMDA: milestone listed for Q4 2026 / Q1 2027, and PMDA acceptance of the submission.
- FDA written feedback or meeting on the Helix Pre-Submission: company expects feedback in about six weeks, with a Helix FDA De Novo pre-submission meeting listed for Q4 2026.
- Helix De Novo submission in Q1 2027, with approval in mid-2027 if FDA meets its 150-review-day target, as stated by the company.
- Publication of the peer-reviewed CardiAMP HF manuscript: listed for Q1 2027.
- CardiAMP HF II enrollment: four sites enrolling and seven additional sites being onboarded, per the company.
- Heart3D FDA submission: listed for Q1 2027. Gene therapy study with partner(s) using Helix and Heart3D: listed for Q1 2027.
- Cash position and financing: the company states runway into 2027 with $2.2 million of cash at quarter end. Any new financing is not described in the document.
Balance sheet and cash flow
- Cash and cash equivalents: $2,224 thousand at Sept 30, 2026, compared with $2,496 thousand at Dec 31, 2025 (balance sheet data, not a prior-year comparison).
- Total assets: $3,071 thousand at Sept 30, 2026, compared with $3,413 thousand at Dec 31, 2025.
- Current liabilities: $2,092 thousand at Sept 30, 2026, compared with $2,432 thousand at Dec 31, 2025.
- Operating lease liability, noncurrent: $144 thousand at Sept 30, 2026, compared with $86 thousand at Dec 31, 2025.
- Total stockholders' equity: $835 thousand at Sept 30, 2026, compared with $895 thousand at Dec 31, 2025.
- The company states it ended the quarter with cash and cash equivalents totaling $2.2 million, providing anticipated runway into 2027.
- Net cash used in operations was $1.7 million for the three months ended September 2026 and $1.7 million for the three months ended September 2025. For the nine months it was $5.1 million in 2026 and $4.9 million in 2025. The company attributes the nine-month increase primarily to the timing of supplier payments.
Analysis
BioCardia reported third-quarter 2026 results with no revenue line in the filing. The quarter's operating loss was $(1,835) thousand against $(1,488) thousand a year earlier, and the net loss was $(1,817) thousand against $(1,483) thousand. Research and development rose to $1,235 thousand from $936 thousand, and the company attributes this to a higher bonus accrual, Japan regulatory work and enrollment in the CardiAMP HF II trial. SG&A rose to $600 thousand from $552 thousand. Net loss per share was $(0.12) against $(0.24), a figure the filing presents next to a much larger weighted share count.
On a nine-month basis the picture is different. Research and development fell to $3,363 thousand from $3,834 thousand, and the company attributes the decrease mainly to closeout of the CardiAMP Heart Failure Trial, partly offset by early HF II enrollment and Japan regulatory activity. The nine-month operating loss narrowed to $(5,724) thousand from $(6,265) thousand, and the net loss to $(5,689) thousand from $(6,244) thousand. Nine-month net loss per share was $(0.45) against $(1.17). Net cash used in operations was $5.1 million for the nine months, against $4.9 million a year earlier, which the company ties mainly to the timing of supplier payments.
The balance sheet is small. Cash and cash equivalents were $2,224 thousand at Sept 30, 2026, down from $2,496 thousand at Dec 31, 2025, and total assets were $3,071 thousand. Stockholders' equity was $835 thousand, against $895 thousand at year-end 2025. The company states it has cash providing anticipated runway into 2027. The filing does not include a going-concern statement or any financing arrangement, so the runway claim rests on the company's own statement.
The guide is milestone-based rather than numerical. The company says it has completed the process with PMDA on application materials for Japan, with a submission listed for Q4 2026 or Q1 2027. It expects FDA feedback on the Helix Pre-Submission within about six weeks and plans a De Novo submission in Q1 2027, with approval in mid-2027 if FDA meets its target. A peer-reviewed CardiAMP HF manuscript and a Heart3D FDA submission are both listed for Q1 2027. The filing gives no revenue, margin or earnings guidance.
The figures that deserve attention are the cash balance relative to the nine-month cash burn, the widening of the quarterly loss against the narrowing of the nine-month loss, and the regulatory dates that the company itself lists. The 10-Q referenced in the release was not part of the text supplied, so balance-sheet detail beyond the selected data is not available here.
Management, verbatim
We believe that our CardiAMP autologous cell therapy is on track to be the first approved minimally invasive biologic therapy for the treatment of heart failure in a first world country based on the recent interactions with Japan’s Pharmaceutical and Medical Devices Agency,
Peter Altman, PhD, Chief Executive Officer
This promises to be an exciting year ahead.
Peter Altman, PhD, Chief Executive Officer
Not in the filing
stated, not guessed- Revenue: the filing reports no revenue or sales line for any period.
- Gross margin, cost of sales and income tax lines: not presented in the statement of operations.
- Year-over-year and quarter-over-quarter percentage changes for any line: not printed in the filing.
- Prior-quarter (Q2 2026) figures: not printed in the filing.
- Cash and cash equivalents at Sept 30, 2025 (the prior-year comparison): not printed in the filing.
- Financial guidance (revenue, margins, operating expenses, tax rate): no financial guidance is provided in the filing.
- Prior-period outlook: not supplied, so the vs_prior_guidance comparison is empty.
- Capital returns (share repurchases, dividends): not reported in the filing.
- Detailed cash flow statement and financing activity: not in the filing; only the selected operating cash use figures are printed in the text.
- Financing arrangements or going-concern language: not stated in the filing.
- Form 10-Q: referenced in the release but not included in the supplied text.
- Segment or product-line revenue breakdown: none reported.
- Non-GAAP reconciliation: none presented.
- Share price reaction and analyst consensus: not in the filing and not included.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
BioCardia is a Nasdaq‑listed micro‑cap focused on autologous cell therapies for heart failure and a novel transendocardial delivery system.
Ticker impact
BioCardia filed its 8‑K reporting Q3 2026 results, disclosing cash balance, net loss, and regulatory milestones for CardiAMP and Helix.
likely pressure as the market prices in the cash shortfall and loss, with upside potential on positive regulatory news.
New financial figures and regulatory updates are primary disclosures; the cash balance of $2.2 M limits runway, but upcoming submissions to FDA and PMDA are catalysts.
Market effects
Highlights ongoing development activity in the cell‑therapy and medical‑device space, potentially influencing peer biotech valuations.
Limited to U.S. and Japan biotech investors tracking regulatory pathways.
Modest; primarily relevant to niche cardiovascular‑therapy investors.
Counterpoint
Despite the loss, the company’s unique delivery platform could command a premium if FDA clearance is achieved, suggesting a longer‑term upside.
Key entities
- ExecutivePeter Altman
CEO of BioCardia, quoted on regulatory progress.
- PartnerCART‑Tech
Development and commercial partner for Helix and Heart3D platforms.


